MedTrace Logo

Efficacy and Safety on Prouk for STEMI Patients in China

NCT02367976 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2015-02-25

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of rh-prouk as pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed as a multicenter, active controlled, single blinded study. The primary endpoint is to assess the coronary recanalization 90 minutes after thrombolysis. The secondary endpoint is to evaluate the mortality rate at day 30.

Conditions

  • STEMI

Interventions

DRUG

rhprouk

rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed

Sponsors & Collaborators

  • Suzhou RxD Biopharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Weiqun Shen, MD/PhD · Suzhou RxD Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02367976 on ClinicalTrials.gov